Cortexyme Overview

  • Founded
  • 2012
Founded
  • Status
  • Public
  • Employees
  • 38
Employees
  • Stock Symbol
  • CRTX
Stock Symbol
  • Share Price
  • $36.77
  • (As of Friday Closing)

Cortexyme General Information

Description

Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains. The company operates in only one reportable segment that is developing and commercializing therapeutics.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 269 East Grand Avenue
  • Verily Campus
  • South San Francisco, CA 94080
  • United States

Cortexyme Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cortexyme Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$36.77 $34.33 $26.66 - $58.99 $1.09B 29.6M 289K -$2.80

Cortexyme Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 931,151 681,904 1,387,028
Revenue 0 0 0 0
EBITDA (84,013) (78,561) (38,980) (12,274)
Net Income (82,759) (76,849) (36,980) (12,476)
Total Assets 174,522 189,466 124,370 72,877
Total Debt 171 208 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cortexyme Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cortexyme‘s full profile, request access.

Request a free trial

Cortexyme Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Cortexyme‘s full profile, request access.

Request a free trial

Cortexyme Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat
Biotechnology
South San Francisco, CA
38 As of 2020
00000
000000000 00000

0000000

tate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proide
0000 000000000
South San Francisco, CA
000 As of 0000
00000
00000000 00000

0000000

iusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exe
0000 000000000
Cambridge, MA
00 As of 0000
00000
0000 0000-00-00
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cortexyme Competitors (28)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alector Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
0000000 Venture Capital-Backed Framingham, MA 00 000.00 0000000000 000.00
000000000 Formerly VC-backed Thebarton, Australia 000.00 000000000 000.00
You’re viewing 5 of 28 competitors. Get the full list »

Cortexyme Executive Team (16)

Name Title Board Seat Contact Info
Casey Lynch Co-Founder & Chief Executive Officer
Christopher Lowe Chief Financial Officer and Chief Operating Officer
Ted Monohon Chief Accounting Officer, Accounting
Caryn McDowell Chief Administrative Officer, Administration & Secretary, Administration
Stephen Dominy MD Co-Founder & Chief Scientific Officer
You’re viewing 5 of 16 executive team members. Get the full list »

Cortexyme Board Members (10)

Name Representing Role Since
Casey Lynch Cortexyme Co-Founder & Chief Executive Officer 000 0000
Christopher Senner Cortexyme Board Member 000 0000
David Lamond Lamond Capital Partners Board Member 000 0000
Kevin Young Cortexyme Board Member 000 0000
Margi McLoughlin Ph.D Pfizer Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Cortexyme Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cortexyme Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cortexyme‘s full profile, request access.

Request a free trial